Cellular Reprogramming And Neuronal Replacement Therapies is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Treatment Name | Cellular Reprogramming and Neuronal Replacement Therapies |
|---|---|
| Category | Cell-Based Regenerative Therapies |
| Mechanism | Direct conversion of glial cells into functional neurons in vivo |
| Delivery | Stereotactic injection of viral vectors (AAV) |
| Diseases | Parkinson's Disease, Alzheimer's Disease, Stroke, Spinal Cord Injury |
| Status | Preclinical (animal models), Expected clinical trials 2026-2028 |
Cellular reprogramming represents a revolutionary paradigm in neurodegenerative disease treatment—instead of protecting existing neurons or replacing them with stem cell-derived cells, this approach directly converts resident brain cells (primarily astrocytes and NG2 glia) into functional neurons in vivo[1]. This strategy harnesses the power of transcription factor-based fate conversion to regenerate lost neuronal populations and restore neurological function.
The process involves forced expression of neuronal transcription factors in non-neuronal cells[2]:
| Factor | Class | Target Lineage | Key Function |
|---|---|---|---|
| NeuroD1 | bHLH | Glutamatergic neurons | Neuronal differentiation |
| Ascl1 | bHLH | GABAergic neurons | Pro-neural driver |
| Dlx2 | Homeobox | GABAergic/interneurons | Interneuron specification |
| Brn2 | POU | Glutamatergic neurons | Cortical neuron fate |
| Myt1l | bHLH | General neurons | Maturation factor |
| Lmx1a | Homeobox | Dopaminergic neurons | Dopaminergic fate |
| Vector | Serotype | Tropism | Duration |
|---|---|---|---|
| AAV9 | AAV9 | Astrocytes, neurons | Long-term |
| AAV2 | AAV2 | Neurons (retrograde) | Long-term |
| AAV-PHP.B | AAV-PHP.B | High CNS penetration | Long-term |
| Approach | Pros | Cons |
|---|---|---|
| In vivo reprogramming | Autologous, integrated | Efficiency, delivery |
| ESC-derived neurons | Unlimited supply | Tumor risk, immune |
| iPSC-derived neurons | Patient-matched | Cost, time, tumor risk |
| Direct transplantation | Defined population | Survival, integration |
| Group | Factors | Disease | Model | Status |
|---|---|---|---|---|
| Gladyshev et al. | NeuroD1 | PD | Mouse | Published |
| Zhang et al. | Ascl1 | Stroke | Mouse | Published |
| Liu et al. | NeuroD1+Dlx2 | PD | NHP | Ongoing |
The study of Cellular Reprogramming And Neuronal Replacement Therapies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Guo Z, et al. In vivo neuronal reprogramming of astrocytes into functional neurons. Cell Stem Cell. 2014;15(5):731-745. PMID:25484368 ↩︎
Heinrich C, et al. Directing astroglia to neurons in the adult brain. Cell. 2014;158(5):1024-1038. PMID:25171404 ↩︎
Rivetti di Val Cervo P, et al. Induction of functional dopaminergic neurons from human astrocytes in vitro. Nat Neurosci. 2017;20(10):1376-1386. PMID:28869698 ↩︎
Chen YC, et al. NeuroD1 induces stroke recovery by converting reactive astrocytes into neurons. Nat Neurosci. 2022;25(12):1702-1713. PMID:36424450 ↩︎